Design, synthesis, and biological evaluation of (hydroxyphenyl)naphthalene and -quinoline derivatives: Potent and selective nonsteroidal inhibitors of 17β-hydroxysteroid dehydrogenase type 1 (17β-HSD1) for the treatment of estrogen-dependent diseases

Journal of Medicinal Chemistry

Volumn 51, Issue 7, 2008, Pages 2158-2169

  Frotscher, Martin ^a   Ziegler, Erika ^a   Marchais Oberwinkler, Sandrine ^a   Kruchten, Patricia ^a   Neugebauer, Alexander ^a   Fetzer, Ludivine ^a   Scherer, Christiane ^a   Müller Vieira, Ursula ^b   Messinger, Josef ^c   Thole, Hubert ^c   Hartmann, Rolf W ^a  

^a SAARLAND UNIVERSITY   (Germany)

^b Pharmacelsus CRO   (Germany)

^c Solvay Pharmaceuticals GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

17BETA HYDROXYSTEROID DEHYDROGENASE TYPE 1; 2 METHOXY 6 (2 METHOXYHENYL)NAPHTHALENE; 2 METHOXY 6 (3 NITROPHENYL)NAPHTHALENE; 3 (3 METHOXYPHENYL)QUINOLINE; 3 (4 METHOXYPHENYL)QUINOLINE; 3 (6 HYDROXY 2 NAPHTHYL)BENZOIC ACID; 3 (6 METHOXY 2 NAPHTHYL)PHENYLAMINE; 3 BROMO 7 METHOXYQUINOLINE; 3 METHOXY 5 (6 METHOXY 2 NAPHTHYL)PYRIDINE; 4 (6 HYDROXY 2 NAPHTHYL)BENZOIC ACID; 5 METHOXY 2 (3 METHOXYPHENYL) 1H INDOLE; 6 (2 THIENYL) 2 NAPHTHOL; 6 (3 THIENYL) 2 NAPHTHOL; 6 (4 METHOXYPHENYL) 1 NAPHTHOL; 6 [3 (HYDROXYMETHYL)PHENYL] 2 NAPHTHOL; 6 [4 (HYDROXYMETHYL)PHENYL] 2 NAPHTHOL; 6 PHENYL 2 NAPHTHOL; 6 PYRIDIN 3 YL 2 NAPHTHOL; 7 METHOXY 3 (3 METHOXYPHENYL)QUINOLINE; 7 METHOXY 3 (4 METHOXYPHENYL)QUINOLINE; ESTRADIOL; ESTROGEN RECEPTOR; ESTRONE; LIVER ENZYME; N [3 (6 HYDROXY 2 NAPHTHYL)PHENYL]ACETAMIDE; NAPHTHALENE DERIVATIVE; PHENYLNAPHTHALENE; QUINOLINE DERIVATIVE; TESTOSTERONE 17BETA DEHYDROGENASE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANIMAL CELL; ARTICLE; BIOLOGY; BREAST TUMOR; CELL MEMBRANE PERMEABILITY; CHEMICAL REACTION; DRUG DESIGN; DRUG SELECTIVITY; DRUG SYNTHESIS; ENZYME MECHANISM; ESTROGEN DEFICIENCY; HUMAN; HUMAN CELL; INTROSPECTION; LIVER MICROSOME; MALE; NONHUMAN; PROTEIN INTERACTION; RAT;

17-HYDROXYSTEROID DEHYDROGENASES; ANIMALS; ARYL HYDROCARBON HYDROXYLASES; BINDING SITES; CACO-2 CELLS; COMPUTER SIMULATION; DRUG DESIGN; ENZYME INHIBITORS; ESTROGENS; HUMANS; HYDROGEN BONDING; LIVER; MALE; MICROSOMES, LIVER; MODELS, MOLECULAR; MOLECULAR STRUCTURE; NAPHTHALENES; NEOPLASMS, HORMONE-DEPENDENT; QUINOLINES; RATS; RATS, SPRAGUE-DAWLEY; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 41849117998     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm701447v     Document Type: Article

References (54)

1. Travis, R. C.; Key, T. J. Estrogen exposure and breast cancer risk. Breast Cancer Res. 2003, 5, 239-247.
2. Dizerega, G. S.; Barber, D. L.; Hodgen, G. D. Endometriosis: Role of ovarian steroids in initiation, maintenance and suppression. Fert. Steril. 1980, 33, 649-653.
3. Miller, W. R.; Bartlett, J. M. S.; Canney, P.; Verrill, M. Hormonal therapy for postmenopausal breast cancer: the science of sequencing. Breast Cancer Res. Treat. 2007, 103, 149-160.
4. Bush, N. J. Advances in hormonal therapy for breast cancer. Semin. Oncol. Nursing, 2007, 23, 46-54.
5. Lukacik, P.; Kavanagh, K.; Oppermann, U. Structure and function of human 17β-hydroxysteroid dehydrogenases. Mol. Cell. Endocrinol. 2006, 248, 61-71.
6. Labrie, F. Intracrinology. Mol. Cell. Endocrinol. 1991, 78, C113-C118.
7. Miyoshi, Y.; Ando, A.; Shiba, E.; Taguchi, T.; Tamaki, Y.; Noguchi, S. Involvement of up-regulation of 17beta-hydroxysteroid dehydrogenase type 1 in maintenance of intratumoral high estradiol levels in postmenopausal breast cancers. Int. J. Cancer 2001, 94, 685-689.
8. Miettinen, M.; Isomaa, V.; Peltoketo, H.; Ghosh, D.; Vihko, P. Estrogen metabolism as a regulator of estrogen action in the mammary gland. J. Mammary Gland. Biol. Neoplasia 2000, 5, 259-270.
9. Peltoketo, H.; Isomaa, V.; Maentausta, O.; Vihko, R. Complete amino acid sequence of human placental 17β-hydroxysteroid dehydrogenase deduced from cDNA. FEBS Lett. 1988, 239, 73-77.
10. Jin, J. Z.; Lin, S.-X. Human estrogenic 17β-hydroxysteroid dehydrogenase: predominance of estrone reduction and its induction by NADPH. Biochem. Biophys. Res. Commun. 1999, 259, 489-493.
11. Takeyama, J.; Suzuki, T.; Hirasawa, G.; Muramatsu, Y.; Nagura, H.; Iinuma, K.; Nakamura, J.; Kimura, K.-I.; Yoshihama, M.; Harada, N.; Andersson, S.; Sasano, H. 17β-Hydroxysteroid dehydrogenase type 1 and 2 expression in the human fetus. J. Clin. Endocrinol. Metab. 2000, 85, 410-416.
12. Schwabe, I.; Husen, B.; Einspanier, A. Expression of the estradiol-synthesizing 17β-hydroxysteroid dehydrogenases type 1 and type 7 in the nonhuman primate callithrix jacchus. Mol. Cell. Endocrinol. 2001, 171, 187-192.
13. Azzi, A.; Rehse, P. H.; Zhu, D. W.; Campbell, R. L.; Labrie, F.; Lin, S.-X. Crystal structure of human estrogenic 17beta-hydroxysteroid dehydrogenase complexed with 17 beta-estradiol. Nat. Struct. Biol. 1996, 3, 665-668.
14. Breton, R.; Housset, D.; Mazza, C.; Fontecilla-Camps, J. C. The structure of a complex of human 17beta-hydroxysteroid dehydrogenase with estradiol and NADP+ identifies two principal targets for the design of inhibitors. Structure 1996, 4, 905-915.
15. Gangloff, A.; Shi, R.; Nahoum, V.; Lin, S.-X. Pseudo-symmetry of C19 steroids, alternative binding orientations, and multispecificity in human estrogenic 17beta-hydroxysteroid dehydrogenase. FASEB J. 2003, 17, 274-276.
16. Ghosh, D.; Pletnev, V. Z.; Zhu, D. W.; Wawrzak, Z.; Duax, W. L.; Pangborn, W.; Labrie, F.; Lin, S.-X. Structure of human estrogenic 17beta-hydroxysteroid dehydrogenase at 2.20 Å resolution. Structure 1995, 3, 503-513.
17. Han, Q.; Campbell, R. L.; Gangloff, A.; Huang, Y. W.; Lin, S.-X. Dehydroepiandrosterone and dihydrotestosterone recognition by human estrogenic 17beta-hydroxysteroid dehydrogenase. C-18/C-19 steroid discrimination and enzyme-induced strain. J. Biol. Chem. 2000, 275, 1105-1111.
18. Mazza, C.; Breton, R.; Housset, D.; Fontecilla-Camps, J. C. Unusual charge stabilization of NADP+ in 17beta-hydroxysteroid dehydrogenase. J. Biol. Chem. 1998, 273, 8145-8152.
19. Qiu, W.; Campbell, R. L.; Gangloff, A.; Dupuis, P.; Boivin, R. P.; Tremblay, M. R.; Poirier, D.; Lin, S.-X. A concerted, rational design of type 1 17beta-hydroxysteroid dehydrogenase inhibitors: estradiol-adenosine hybrids with high affinity. FASEB J. 2002, 16, 1829-1831.
20. Sawicki, M. W.; Erman, M.; Puranen, T.; Vihko, P.; Ghosh, D. Structure of the ternary complex of human 17beta-hydroxysteroid dehydrogenase type 1 with 3-hydroxyestra-1,3,5,7-tetraen-17-one (equilin) and NADP+. Proc. Natl. Acad. Sci. U.S.A. 1999, 96, 840-845.
21. Shi, R.; Lin, S.-X. Cofactor hydrogen bonding onto the protein main chain is conserved in the short chain dehydrogenase/reductase family and contributes to nicotinamide orientation. J. Biol. Chem. 2004, 279, 16778-16785.
22. Poirier, D. Inhibitors of 17beta-hydroxysteroid dehydrogenases. Curr. Med. Chem. 2003, 10, 453-477.
23. Penning, T. M. 17β-hydroxysteroid dehydrogenase: Inhibitors and inhibitor design. Endocr. Relat. Cancer 1996, 3, 41-56.
24. Vihko, P.; Isomaa, V. Method for prognosticating the progress of breast cancerandcompoundsuseful for pevention or treatment thereof. WO2004080271, 2004.
25. Wähälä, K.; Lilienkampf, A.; Alho, S.; Huhtinen, K.; Johansson, N.; Koskimies, P.; Vihko, K. Thiophenopyrimidinones as 17β-hydroxysteroid dehydrogenase inhibitors. WO2004110459, 2004.
26. Hirvelä, L. Novel Compounds and their Use in Therapy. WO2005032527, 2005.
27. Messinger, J.; Thole, H.; Husen, B.; Van Steen, B. J.; Schneider, G.; Hulshof, J.; Koskimies, P. Novel 17beta-hydroxysteroid dehydrogenase type 1 Inhibitors. WO2005047303, 2005.
28. Poirier, D.; Boivin, R. P.; Tremblay, M. R.; Beruhe, M.; Qiu, W.; Lin, S. X. Estradiol-adenosine hybrid compounds designed to inhibit type 1 17beta-hydroxysteroid dehydrogenase. J. Med. Chem. 2005, 48, 8134-8147.
29. Poirier, D.; Chang, H. J.; Azzi, A.; Boivin, R. P.; Lin, S.-X. Estrone and estradiol C-16 derivatives as inhibitors of type 1 17beta-hydroxysteroid dehydrogenase. Mol. Cell. Endocrinol. 2006, 248, 236-238.
30. Allan, G. M.; Bubert, C.; Vicker, N.; Smith, A.; Tutill, H. J.; Purohit, A.; Reed, M. J.; Potter, B. V. Novel potent inhibitors of 17beta-hydroxysteroid dehydrogenase type 1. Mol. Cell. Endocrinol. 2006, 248, 204-207.
31. Allan, G. M.; Lawrence, H. R.; Cornet, J.; Bubert, C.; Fischer, D. S.; Vicker, N.; Smith, A.; Tutill, H. J.; Purohit, A.; Day, J. M.; Mahon, M. F.; Reed, M. J.; Potter, B. V. Modification of estrone at the 6, 16, and 17 positions: novel potent inhibitors of 17beta-hydroxysteroid dehydrogenase type 1. J. Med. Chem. 2006, 49, 1325-1345.
32. Messinger, J.; Hirvela, L.; Husen, B.; Kangas, L.; Koskimies, P.; Pentikainen, O.; Saarenketo, P.; Thole, H. New inhibitors of 17beta-hydroxysteroid dehydrogenase type 1. Mol. Cell. Endocrinol. 2006, 248, 192-198.
33. Hillisch, A.; Regenhardt, W.; Gege, C.; Peters, O.; Bothe. U.; Adamski, J.; M̈oller, G.; Rosinus, A.; Elger, W.; Schneider, B. Novel 2-substituted estra-1,3,5(10)-trien-17-ones used in the form of inhibitors of 17β-hydroxysteroiddehydrogenase of type 1. WO2006003013 A2, 2006.
34. Vicker, N.; Allan, G. M.; Lawrence, H. R. R.; Day, J. M.; Purohit, A.; Reed, M. J.; Potter, B. V. L. Compound. WO2007096647 A2, 2007.
35. Neugebauer, A.; Hartmann, R. W. Protein dynamics of 17β- hydroxysteroid dehydrogenase type 1. Bioorg. Med. Chem. 2007, submitted for publication.
36. Mewshaw, R. E.; Edsall, R. J., Jr.; Yang, C.; Manas, E. S.; Xu, Z. B.; Henderson, R. A.; Keith, J. C., Jr.; Harris, H. A. ERbeta ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERβ selectivity. J. Med. Chem. 2005, 48, 3953-3979.
37. Miyaura, N.; Suzuki, A. The palladium catalyzed cross-coupling reaction of phenylboronic acid with haloarenes in the presence of bases. Synth. Commun. 1981, 11, 513-519.
38. von Angerer, E.; Prekajac, J.; Strohmeier, J. 2-Phenylindoles. Relationsship between structure, estrogen receptor affinity, and mammary tumor inhibiting activity in rat. J. Med. Chem. 1984, 27, 1439-1447.
39. Song, S.; Lee, H.; Jin, Y.; Ha, Y. M.; Bae, S.; Chung, H. Y.; Suh, H. Syntheses of hydroxy substituted 2-phenyl-naphthalenes as inhibitors of tyrosinase. Bioorg. Med. Chem. Lett. 2007, 17, 461-464.
40. Chen, W.; Lin, Z.; Ning, M.; Yang, C.; Yan, X.; Xie, Y.; Shen, X.; Wang, M.-W. Aza analogues of equol: Novel ligands for estrogen receptors beta. Bioorg. Med. Chem. 2007, 15, 5828-5836.
41. Hidalgo, I. J. Assessing the absorption of new pharmaceuticals. Curr. Top. Med. Chem. 2001, 1, 385-401.
42. Narasimha, M. J.; Parthasarathy, V.; Subhas, S.; Krishna, K. D. Photochromism of arylchromenes:remarkable modification of absorption properties and lifetimes of o-quinonoid intermediates. Org. Lett. 2007, 9, 919-922.
43. Kamenikova, L. A biotransformation study of some substances with analgesic effect. Folia Pharm. 1982, 4, 37-71.
44. Puranen, T. J.; Poutanen, M. H.; Peltoketo, H. E.; Vihko, P. T.; Vihko, R. K. Site-directed mutagenesis of the putative active site of human 17beta-hydroxysteroid dehydrogenase type 1. Biochem. J. 1994, 304, 289-293.
45. Lin, S.-X.; Yang, F.; Jin, J.-Z.; Breton, R.; Zhu, D.-W.; Luu-The, V; Labrie, F. Subunit identity of the dimeric 17β-hydroxysteroid dehydrogenase from human placenta. J. Biol. Chem. 1992, 267, 16182-16187.
46. Sam, K. M.; Auger, S.; Luu-The, V.; Poirier, D. Steroidal spirogamma-lactones that inhibit 17beta-hydroxysteroid dehydrogenase activity in human placental microsomes. J. Med. Chem. 1995, 38, 4518-4528.
47. Sam, K. M.; Boivin, R. P.; Tremblay, M. R.; Auger, S.; Poirier, D. C16 and C17 derivatives of estradiol as inhibitors of 17beta-hydroxysteroid dehydrogenase type 1: chemical synthesis and structure-activity relationships. Drug Des. Discov. 1998, 15, 157-180.
48. Zimmermann, J.; Liebl, R.; von Angerer, E. 2,5-Diphenylfuran-based pure antiestrogens with selectivity for the estrogen receptor a. J. Steroid Biochem. Mol. Biol. 2005, 94, 57-66.
49. Yee, S. In vitro permeability across Caco-2 cells (colonic) can predict in vivo (small intestinal) absorption in man-fact or myth. Pharm. Res. 1997, 14, 763-766.
50. MacroModel 8.1, Schrödinger Inc., 2003.
51. Jones, G.; Willett, P.; Glen, R. C.; Leach, A. R.; Taylor, R. Development and validation of a genetic algorithm for flexible docking. J. Mol. Biol. 1997, 267, 727-748.
52. Case, D. A.; Perlman, D. A.; Caldwell, J. W.; Wang, J.; Ross, W. S.; Simmerling, C.; Darden, T.; Merz, K. M.; Stanton, R. V.; Cheng, A.; Vincent, J. J.; Crowley, M.; Tsui, V.; Gohlke, H. R. R.; Duan, Y.; Pitera, J.; Massavo, I.; Seibel, G. L.; Singh, U. C.; Weiner, P.; Kollman, P. A. Amber 8, University of California, San Francisco, 2004.
53. Berendsen, H. J.; Postma, J. P. M.; van Gunsteren, W. F.; Di Nola, A.; Haak, J. R. Molecular dynamics with coupling to an external bath. Chem. Phys. 1984, 81, 3684-3690.
54. Tsui, V.; Case, D. A. Theory and applications of the generalized Born solvation model in macromolecular simulations. Biopolymers 2000, 56, 275-291.